Liquid Biopsy Market Size to Worth USD 28.84 Billion by 2033 | Straits Research
21 nov. 2024 09h55 HE
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 21, 2024 (GLOBE NEWSWIRE) -- "Liquid biopsy" isolates and detects circulating nucleic acids (DNA or RNA), exosomes, and circulating tumor cells to diagnose primary...
KOELIS announces the first interim results of the VIOLETTE trial which evaluates the use of OBT-Fusion® technology in focal ablation of the prostate by microwave needles
20 nov. 2024 09h00 HE
|
Koelis
GRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today passing an important...
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
19 nov. 2024 03h30 HE
|
Curium
ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
15 nov. 2024 21h15 HE
|
Precede Biosciences, Inc.
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic response to Lutetium-PSMABeyond Lutetium-PSMA, these results are...
Artificial Intelligence Revolutionizing the Future of Oncology: Market Set to Soar to US$8.944 Billion by 2029 | 2024 Research Report
14 nov. 2024 10h21 HE
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. The...
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14 nov. 2024 08h00 HE
|
Candel Therapeutics
On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk prostate cancer, expected in Q4 2024On track for...
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
13 nov. 2024 10h57 HE
|
Curium
ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
07 nov. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
06 nov. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Media Advisory and Interview Opportunity: Movember Joins Forces with Jon Montgomery on a Moustache Mission for Men’s Health
01 nov. 2024 05h00 HE
|
Movember Canada
TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- It’s Movember 1 and Canada’s hairiest campaign is back to raise awareness, education and important funds for men’s health. This year, Olympian and...